A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants

Model scores of the 29,894 trials active now.

Model score 4% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 9% of the time (238 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-11-14. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: eyedose ofmsecthe followingbowel
  Phrases that lowered it: healthyparticipantparticipantsthe pharmacokineticsthe trial
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 12.8% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 32.3% (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 0.4% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 65 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Sponsor's past trials: 658 (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: none (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 3 (lowers risk) · Design
• Maximum age: 55 (lowers risk) · Who can join
• Drug's FAERS reports before start: 2109 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of TEPEZZA Subcutaneous Administration in Healthy Adults NCT06563856 · started 2020 · scored riskier than 3% of active trials completed
• Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study NCT03298867 · started 2017 · scored riskier than 42% of active trials completed
• Phase I Study to Evaluate rhTPO in Healthy Caucasian Volunteers NCT06630494 · started 2024 · scored riskier than 2% of active trials completed
• Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers NCT03021642 · started 2016 · scored riskier than 1% of active trials completed
• A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants NCT07142642 · started 2025 · scored riskier than 4% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.